Market Cap | 1.63B | P/E | - | EPS this Y | 15.40% | Ern Qtrly Grth | - |
Income | -150.22M | Forward P/E | -11.59 | EPS next Y | -19.00% | 50D Avg Chg | -2.00% |
Sales | 8.3M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -9.00% |
Dividend | N/A | Price/Book | 5.37 | EPS next 5Y | - | 52W High Chg | -29.00% |
Recommedations | 1.80 | Quick Ratio | 29.06 | Shares Outstanding | 66.29M | 52W Low Chg | 27.00% |
Insider Own | 0.30% | ROA | -17.83% | Shares Float | 66.10M | Beta | 1.56 |
Inst Own | 107.22% | ROE | -27.53% | Shares Shorted/Prior | 8.41M/8.66M | Price | 34.43 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 445,538 | Target Price | 67.11 |
Oper. Margin | -1,854.16% | Earnings Date | Oct 31 | Volume | 310,948 | Change | -0.95% |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Wells Fargo | Equal-Weight | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
Cantor Fitzgerald | Overweight | Jul 30, 24 |
HC Wainwright & Co. | Buy | Jul 30, 24 |
HC Wainwright & Co. | Buy | Jul 16, 24 |
Cantor Fitzgerald | Overweight | Jun 18, 24 |
Wolfe Research | Outperform | Jun 11, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Young Diane C. | SVP, CHIEF MEDICAL O.. SVP, CHIEF MEDICAL OFFICER | Aug 17 | Option | 6.55 | 64,000 | 419,200 | 47,115 | 08/19/22 |
Young Diane C. | SVP, CHIEF MEDICAL O.. SVP, CHIEF MEDICAL OFFICER | Aug 17 | Sell | 37.3 | 19,000 | 708,700 | 2,115 | 08/19/22 |